Table 6 The most frequent (≥2)a QT-DDIs along with their levels and TdP risks of drugs involved in these QT-DDIs stratified with respect to various types of cancer
QT-DDIs | TdP risk | Levels of QT-DDIs | Frequency | ||
|---|---|---|---|---|---|
Drug 1 | Drug 2 | Severity | Documentation | QT-DDIs: n (%)b | |
Breast cancer | |||||
Ciprofloxacin-Ondansetron | Known risk of TdP | Known risk of TdP | Major | Fair | 31 (10.8) |
Ciprofloxacin-Prochlorperazine | Known risk of TdP | Not included in lists | Major | Fair | 31 (10.8) |
Ondansetron-Prochlorperazine | Known risk of TdP | Not included in lists | Major | Fair | 31 (10.8) |
Gastrointestinal cancer | |||||
Ondansetron-Prochlorperazine | Known risk of TdP | Not included in lists | Major | Fair | 26 (9) |
Ciprofloxacin-Ondansetron | Known risk of TdP | Known risk of TdP | Major | Fair | 13 (4.5) |
Ciprofloxacin-Prochlorperazine | Known risk of TdP | Not included in lists | Major | Fair | 12 (4.2) |
Dolasetron-Ondansetron | Possible risk of TdP | Known risk of TdP | Major | Fair | 2 (0.7) |
Gynecologic cancer | |||||
Ciprofloxacin-Ondansetron | Known risk of TdP | Known risk of TdP | Major | Fair | 8 (2.8) |
Ciprofloxacin-Prochlorperazine | Known risk of TdP | Not included in lists | Major | Fair | 6 (2.1) |
Ondansetron-Prochlorperazine | Known risk of TdP | Not included in lists | Major | Fair | 6 (2.1) |
Genitourinary cancer | |||||
Ondansetron-Prochlorperazine | Known risk of TdP | Not included in lists | Major | Fair | 7 (2.4) |
Musculoskeletal cancer | |||||
Ciprofloxacin-Ondansetron | Known risk of TdP | Known risk of TdP | Major | Fair | 4 (1.4) |
Ciprofloxacin-Prochlorperazine | Known risk of TdP | Not included in lists | Major | Fair | 4 (1.4) |
Ondansetron-Prochlorperazine | Known risk of TdP | Not included in lists | Major | Fair | 4 (1.4) |
Chronic lymphocytic leukemia | |||||
Dolasetron-Metronidazole | Possible risk of TdP | Conditional risk of TdP | Major | Fair | 3 (1) |
Ciprofloxacin-Dolasetron | Known risk of TdP | Possible risk of TdP | Major | Fair | 2 (0.7) |
Metronidazole-Nilotinib | Conditional risk of TdP | Conditional risk of TdP | Major | Fair | 2 (0.7) |
Non hodgkin lymphoma | |||||
Ciprofloxacin-Metronidazole | Known risk of TdP | Conditional risk of TdP | Major | Fair | 2 (0.7) |
Ciprofloxacin-Ondansetron | Known risk of TdP | Known risk of TdP | Major | Fair | 2 (0.7) |
Ondansetron-Prochlorperazine | Known risk of TdP | Not included in lists | Major | Fair | 2 (0.7) |
Adenocarcinoma | |||||
Ciprofloxacin-Ondansetron | Known risk of TdP | Known risk of TdP | Major | Fair | 2 (0.7) |
Ciprofloxacin-Prochlorperazine | Known risk of TdP | Not included in lists | Major | Fair | 2 (0.7) |
Ondansetron-Prochlorperazine | Known risk of TdP | Not included in lists | Major | Fair | 2 (0.7) |
Head and neck cancer | |||||
Ciprofloxacin-Ondansetron | Known risk of TdP | Known risk of TdP | Major | Fair | 2 (0.7) |
Ciprofloxacin-Prochlorperazine | Known risk of TdP | Not included in lists | Major | Fair | 2 (0.7) |
Ondansetron-Prochlorperazine | Known risk of TdP | Not included in lists | Major | Fair | 2 (0.7) |
Neurological cancer | |||||
Ondansetron-Prochlorperazine | Known risk of TdP | Not included in lists | Major | Fair | 2 (0.7) |
Chronic myelogenous leukemia | |||||
Metronidazole-Nilotinib | Conditional risk of TdP | Conditional risk of TdP | Major | Fair | 2 (0.7) |